Insight Molecular Diagnostics Inc. (IMDX) announced support for the STAR working group’s recent position paper in the American Journal of Transplantation, which calls for decentralized donor-derived cell-free DNA (dd-cfDNA) testing in transplant monitoring. The paper highlights the importance of high-quality, standardized decentralized testing and the diagnostic value of absolute quantification of dd-cfDNA—a key feature of IMDX’s GraftAssure™ family of assays. IMDX’s technology, developed by its scientists in Germany and the U.S., is commercially available through its GraftAssureCore laboratory-developed test and the GraftAssureIQ research-use-only kit. The company is pursuing decentralization of transplant rejection testing, aiming to improve patient care and hospital sustainability in a growing market. The research results referenced are detailed in the recently published position paper.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9624487) on January 13, 2026, and is solely responsible for the information contained therein.